EUCTR2011-002957-67-IT进行中（未招募）不适用
A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects With Progressive Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy Revised Protocol 01 incorporating Administrative Letter 01 and Amendment 02
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 181
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologic confirmation of RCC with a clear cell component. • Previous treatment with at least one anti-angiogenic agent • Progressed within 6 months of study enrollment • Subjects should not have had more than 3 prior treatments for locally advanced or metastatic disease. • Must have available tumor tissue for submission • Subjects must also meet various laboratory parameters for inclusion (see Protocol section 3.3.1 item 4)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 136
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 45
排除标准
- •Active CNS metastases within 30 days of study enrollment • Subjects with any active autoimmune disease or a history of known autoimmune disease • Subjects with uncontrolled adrenal insufficiency • Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured
研究者
相似试验
进行中（未招募）
不适用
A Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell CarcinomaAdvanced/Metastatic renal cell carcinoma with a clear cell componentMedDRA version: 18.0Level: PTClassification code 10038410Term: Renal cell carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002957-67-FIBristol-Myers Squibb International Corporation181
进行中（未招募）
不适用
A Double-Blind, Randomised, Dose-Ranging Study to Compare K-832 with Placebo in the treatment of Patients with Active Rheumatoid Arthritis - N/AMedDRA version: 6.0Level: LLT Classification code 10028395Rheumatoid ArthritisEUCTR2004-000362-12-CZKowa Research Europe Ltd260
进行中（未招募）
1 期
A study to determine how safe and effective maribavir versus Valganciclovir is in treating cytomegalovirus(CMV) in transplant patientsCMV INFECTIONS IN TRANSPLANT RECIPIENTSMedDRA version: 17.0Level: LLTClassification code 10021819Term: Infection in marrow transplant recipientsSystem Organ Class: 100000004862MedDRA version: 17.0Level: LLTClassification code 10021829Term: Infection in solid organ transplant recipientsSystem Organ Class: 100000004862EUCTR2010-024247-32-GBShire ViroPharma Incorporated160
进行中（未招募）
1 期
A study to determine how safe and effective maribavir versus Valganciclovir is in treating cytomegalovirus(CMV) in transplant patientsCMV INFECTIONS IN TRANSPLANT RECIPIENTSMedDRA version: 14.1Level: LLTClassification code 10021819Term: Infection in marrow transplant recipientsSystem Organ Class: 100000004862MedDRA version: 14.1Level: LLTClassification code 10021829Term: Infection in solid organ transplant recipientsSystem Organ Class: 100000004862EUCTR2010-024247-32-BEVIROPHARMA INCORPORATED160
进行中（未招募）
不适用
A study to determine how safe and effective maribavir versus Valganciclovir is in treating cytomegalovirus(CMV) in transplant patients.CMV INFECTIONS IN TRANSPLANT RECIPIENTSMedDRA version: 15.1Level: LLTClassification code 10021819Term: Infection in marrow transplant recipientsSystem Organ Class: 100000004862MedDRA version: 15.1Level: LLTClassification code 10021829Term: Infection in solid organ transplant recipientsSystem Organ Class: 100000004862EUCTR2010-024247-32-ESVIROPHARMA INCORPORATED160